Cargando…

Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway

BACKGROUND: Gemcitabine (GEM) is the first-line chemotherapeutic drug used to treat pancreatic ductal adenocarcinoma carcinoma (PDAC), but chemoresistance is often encountered clinically. Nrf2, an oxidative stress responsive transcription factor, is an important contributor to chemoresistance and po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Juan, Xu, Hong-Xi, Cho, William Chi Shing, Cheuk, Wah, Li, Yang, Huang, Qiong-Hui, Yang, Wen, Xian, Yan-Fang, Lin, Zhi-Xiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908700/ https://www.ncbi.nlm.nih.gov/pubmed/35272669 http://dx.doi.org/10.1186/s13046-022-02270-z

Ejemplares similares

Bruceine A
por: Feng, Xue-Huan, et al.
Publicado: (2010)

Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells
por: Xing, Hai-Bo, et al.
Publicado: (2018)

Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine
por: DUONG, HONG-QUAN, et al.
Publicado: (2013)

Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”
por: Xing, Hai-Bo, et al.
Publicado: (2022)

LW6 enhances chemosensitivity to gemcitabine and inhibits autophagic flux in pancreatic cancer
por: Zhang, Xianbin, et al.
Publicado: (2019)

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling
por: Liu, Jiangbo, et al.
Publicado: (2014)

Girdin Knockdown Increases Gemcitabine Chemosensitivity to Pancreatic Cancer by Modulating Autophagy
por: Wang, Sheng, et al.
Publicado: (2021)

A brief overview of antitumoral actions of bruceine D
por: Sin, Zi Wayne, et al.
Publicado: (2020)

Brucein D, a Naturally Occurring Tetracyclic Triterpene Quassinoid, Induces Apoptosis in Pancreatic Cancer through ROS-Associated PI3K/Akt Signaling Pathway
por: Lai, Zheng-Quan, et al.
Publicado: (2017)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
por: Zhou, Yunjiang, et al.
Publicado: (2019)

Apoptosis induced by bruceine D in human non-small-cell lung cancer cells involves mitochondrial ROS-mediated death signaling
por: Xie, Jian-Hui, et al.
Publicado: (2019)

Self-nanoemulsifying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis
por: Dou, Yao-Xing, et al.
Publicado: (2018)

Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine
por: Zhang, He, et al.
Publicado: (2022)

A novel P38α MAPK activator Bruceine A exhibits potent anti-pancreatic cancer activity
por: Lu, Cai, et al.
Publicado: (2021)

Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma
por: Mao, Yonghuan, et al.
Publicado: (2018)

miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis
por: Yang, Rui-Meng, et al.
Publicado: (2017)

FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
por: Hu, Qiangsheng, et al.
Publicado: (2017)

MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
por: Lu, Huimin, et al.
Publicado: (2019)

Pristimerin Causes G1 Arrest, Induces Apoptosis, and Enhances the Chemosensitivity to Gemcitabine in Pancreatic Cancer Cells
por: Wang, Yongwei, et al.
Publicado: (2012)

Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine
por: Lankadasari, Manendra Babu, et al.
Publicado: (2018)

Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma
por: Suksawat, Manida, et al.
Publicado: (2022)

Metformin Increases the Chemosensitivity of Pancreatic Cancer Cells to Gemcitabine by Reversing EMT Through Regulation DNA Methylation of miR-663
por: Gu, Yuqing, et al.
Publicado: (2020)

Downregulation of miR-183 inhibits the growth of PANC-1 pancreatic cancer cells in vitro and in vivo, and increases chemosensitivity to 5-fluorouracil and gemcitabine
por: Yang, Xiaoping, et al.
Publicado: (2019)

Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer
por: Michalski, C W, et al.
Publicado: (2008)

RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells
por: Yu, C, et al.
Publicado: (2008)

DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53-deficient pancreatic cancer cells
por: Jing, Wei, et al.
Publicado: (2018)

Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer
por: Phan, Thuy, et al.
Publicado: (2021)

HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling
por: Zhou, Yunjiang, et al.
Publicado: (2019)

Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS/MAPK signaling pathway in vitro and in vivo
por: Fan, Jiangjiang, et al.
Publicado: (2020)

dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study
por: Xiong, Junjie, et al.
Publicado: (2016)

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
por: Miller, Aubrey L., et al.
Publicado: (2021)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway
por: Xiang, Yukai, et al.
Publicado: (2018)

Bruceine D inhibits tumor growth and stem cell‐like traits of osteosarcoma through inhibition of STAT3 signaling pathway
por: Wang, Shangyu, et al.
Publicado: (2019)

Chemosensitization as a Means to Augment Commercial Antifungal Agents
por: Campbell, Bruce C., et al.
Publicado: (2012)

Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors
por: Innamarato, Patrick, et al.
Publicado: (2021)

Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells
por: Kreutzer, Jan N, et al.
Publicado: (2010)

Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
por: Tu, Min, et al.
Publicado: (2017)

Targeting SREBP1 chemosensitizes colorectal cancer cells to gemcitabine by caspase-7 upregulation
por: Shen, Wenlong, et al.
Publicado: (2019)

Network-Based Approach to Identify the Antiproliferative Mechanisms of Bruceine D in Breast Cancer From the Cancer Genome Atlas
por: Tian, Saisai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a17okc6o2grtdnec7u5t4kjjid